| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Modifications in the papillary thyroid cancer gene profile over the last 15 years. | J Clin Endocrinol Metab | 2012 | 0.98 |
| 2 | Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. | Int J Cancer | 2011 | 0.87 |
| 3 | The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome. | Thyroid | 2014 | 0.85 |
| 4 | Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. | J Clin Endocrinol Metab | 2013 | 0.78 |